Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals (AVIR) posted quarterly Revenue of $192.2 million for Q4 2021, up 485.72% quarter-over-quarter from $32.8 million in Q3 2021.

Atea Pharmaceuticals (AVIR) Revenue (2021) Analysis & Trends

Atea Pharmaceuticals' Revenue history runs 1 years deep, the most recent figure standing at $192.2 million for Q4 2021.

In Q4 2021, Revenue changed N/A year-over-year to $192.2 million; the TTM figure through Dec 2021 stood at $351.4 million (changed N/A YoY), while the FY2021 annual figure was $351.4 million, up 622.49% from the prior year.
Revenue for Q4 2021 stood at $192.2 million, up from $32.8 million in the prior quarter.
The five-year high for Revenue was $192.2 million in Q4 2021, with the low at $32.8 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Atea Pharmaceuticals	410.65 Mn	410.65 Mn	-	-

Download Data